Modelling the effect of breast cancer screening on related mortality using French data

Cancer Epidemiology

Volumn 35, Issue 3, 2011, Pages 235-242

  Uhry, Z ^a   Hedelin G ^b   Colonna, M ^c   Asselain, B ^d   Arveux, P ^e   Exbrayat, C ^f   Guldenfelds, C ^g   Soler Michel, P ^h   Molinie F ⁱ   Tretarre B ^j   Rogel, A ^a   Courtial, I ^h   Danzon, A ^k   Guizard, A V ^l   Ancelle Park, R ^m   Eilstein, D ^a   Duffy, S ⁿ  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Registre du Cancer de l'Isere   (France)

^d INSTITUT CURIE   (France)

^e EA 4184   (France)

^f Structure de Gestion du Dépistage de l'Isère   (France)

^g Structure de Gestion du Dépistage du Bas Rhin   (France)

^h Structure de Gestion du Dépistage du Rhône   (France)

ⁱ ETS de Loire Atlantique/Vendee   (France)

^j Registre des Tumeurs de l'Herault   (France)

^k Registre des cancers du Doubs   (France)

^l Registre des cancers du Calvados   (France)

^m Ministère de la santé ^*  (France)

ⁿ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

more..

Author keywords

Breast cancer screening; Markov model; Mortality; Natural history; Relative survival

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; EPIDEMIOLOGY; FEMALE; FOLLOW UP; FRANCE; HIDDEN MARKOV MODEL; HUMAN; MAMMOGRAPHY; MEDICAL RECORD; MORTALITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; MAMMOGRAPHY; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; REGISTRIES; SELECTION BIAS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79956034330     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.10.009     Document Type: Article

References (45)

1. IARC handbooks of cancer prevention. vol. 7. Breast cancer screening. Lyon: IARC Press; 2002.
2. Kerlikowske K., Rubin S.M., Sandrock C., Ernster V.L. Efficacy of screening mammography. A meta-analysis. JAMA 1995, 273:149-154.
3. Nyström L., Andersson I., Bjurstam N., Frisell J., Nordenskjöld B., Rutqvist L.E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919.
4. Olsen O., Gotzsche P.C. Cochrane review on screening for breast cancer with mammography. Lancet 2001, 358:1340-1342.
5. Sarkeala T., Heinävaara S., Anttila A. Organised mammography screening reduces breast cancer mortality: a cohort studyfrom Finland. Int J Cancer 2008, 122(3):614-619.
6. Jonsson H., Bordás P., Wallin H., Nyström L., Lenner P. Service screening with mammography in Northern Sweden: effects on breast cancer mortality-an update. J Med Screen 2007, 14(2):87-93.
7. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006, 15(1):45-51. Swedish Organised Service Screening Evaluation Group.
8. Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev 2006, 15(1):52-56. Swedish Organised Service Screening Evaluation Group.
9. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792.
10. van Oortmarssen G.J., Habbema J.D., van der Maas P.J., de Koning H.J., Collette H.J., Verbeek A.L., et al. A model for breast cancer screening. Cancer 1990, 66(7):1601-1612.
11. Tan T., van Oortmarssen G.J., de Koning H.J., Boer R., Habbema J.D. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006, 36:56-65.
12. Arveux P., Wait S., Schaffer P. Building a model to determine the cost-effectiveness of breast cancer screening in France. Eur J Cancer Care 2003, 12(2):143-153.
13. Chen H.H., Duffy S.W., Tabar L., Day N.E. Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. J Epidemiol Biostat 1997, 2:9-23.
14. Chen H.H., Duffy S.W., Tabar L., Day N.E. Markov chain models for progression of breast cancer. Part II: prediction of outcomes for different screening regimes. J Epidemiol Biostat 1997, 2:25-35.
15. Allgood P.C., Warwick J., Warren R.M., Day N.E., Duffy S.W. A case-control study of the impact of the East Anglian breast screening programme on breast cancer mortality. Br J Cancer 2008, 98(1):206-209.
16. Puliti D., Miccinesi G., Collina N., De Lisi V., Federico M., Ferretti S., et al. Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction. Br J Cancer 2008, 99(3):423-427.
17. Duffy S.W., Hill C., Estève J. Quantitative methods for the evaluation of cancer screening 2001, Oxford University Press, New York.
18. Rue M., Vilaprinyo E., Lee S., Carles M.D., Marcos-Gragera R., Pla R., et al. Effectiveness of early detection on breast cancer mortality in Catalonia (Spain). BMC Cancer 2009, 9:326.
19. Uhry Z., Hédelin G., Colonna M., Asselain B., Arveux P., Rogel A., et al. Multistate markov model in cancer screening evaluation: a brief review and a case study. Stat Methods Med Res 2010, 10.1177/0962280209359848.
20. Esteve J., Benhamou E., Croasdale M., Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med 1990, 9(5):529-538.
21. Dickman P.W., Sloggett A., Hills M., Hakulinen T. Regression models for relative survival. Stat Med 2004, 23(1):51-64.
22. Robert-Bobée I, Monteil C. Inégalités sociales de mortalité chez la femme (2005), « Quelles évolutions des différentiels sociaux de mortalité pour les femmes et les hommes? Tables de mortalité par catégorie sociale en 1975, 1982 et 1990 et Indices Standardisés de Mortalité par catégorie sociale en 1975, 1982, 1990 et 1999 », Document de travail, n° F0506, Insee.
23. Day N.E. Overdiagnosis and breast cancer screening. Breast Cancer Res 2005, 7(5):228-229.
24. Duffy S.W., Chen H.H., Tabar L., Day N.E. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 1995, 14(14):1531-1543.
25. Straatman H., Peer P.G.M., Verbeek A.L.M. Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 1997, 53:217-229.
26. Paci E., Duffy S.W. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975-1986). Int J Epidemiol 1991, 20(4):852-858.
27. Brekelmans C.T., Westers P., Faber J.A., Peeters P.H., Collette H.J. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods. J Epidemiol Community Health 1996, 50(1):68-71.
28. Foucher Y., Giral M., Soulillou J.P., Daures J.P. A flexible semi-Markov model for interval-censored data and goodness-of-fit testing. Stat Methods Med Res 2008, 10.1177/0962280208093889.
29. Weedon-Fekjaer H., Lindqvist B.H., Vatten L.J., Aalen O.O., Tretli S. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 2008, 10(3):R41.
30. Duffy S.W., Cuzick J., Tabar L., Vitak B., Chen H.H., Yen M.F., et al. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 2002, 51(2):235-243.
31. Duport N., Ancelle-Park R., Boussac-Zarebska M., Uhry Z., Bloch J. Are breast cancer screening practices associated with sociodemographic status and healthcare access? Analysis of a French cross-sectional study. Eur J Cancer Prev 2008, 17(3):218-224.
32. Biesheuvel C., Barrat A., Howard K., Houssami N., Irwiq L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 2007, 8(12):1129-1137.
33. Hery C., Ferlay J., Boniol M., Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2009, 19:1009-1018.
34. Duffy S.W., Lynge E., Jonsson H., Ayyaz S., Olsen A.H. Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer 2008, 99(7):1176-1178.
35. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356:1670-1674.
36. Parkin D.M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy?. Eur J Cancer 2009, 45(9):1649-1653.
37. Séradour B., Allemand H., Weill A., Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 2009, 96(4):E1-6.
38. Paci E., Miccinesi G., Puliti D., Baldazzi P., De Lisi V., Falcini F., et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res 2006, 8(6):R68.
39. de Koning H.J., Draisma G., Fracheboud J., de Bruijn A. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based onobserved screen and clinical data. Breast Cancer Res 2006, 8(1):202.
40. Morrell S., Barratt A., Irwig L., Howard K., Biesheuvel C., Armstrong B. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography. Cancer Causes Control 2010, 21(2):275-282.
41. Jørgensen K.J., Gøtzsche P.C. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009, 339:b2587.
42. Jonsson H., Johansson R., Lenner P. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005, 117(5):842-847.
43. Seigneurin A., Exbrayat C., Labarère J., Colonna M. Comparison of interval breast cancer rates for two-versus single-view screening mammography: a population-based study. Breast 2009, 18(5):284-288.
44. Schopper D., de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 2009, 45(11):1916-1923.
45. de Gelder R., Bulliard J.L., de Wolf C., et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer 2009, 45(1):127-138.